In­tel­lia ex­its he­mo­phil­ia B pact with Re­gen­eron; Sang­amo tar­gets $24M raise

Plus, news about OKYO Phar­ma:

In­tel­lia de­parts Re­gen­eron deal: The CRISPR biotech dis­closed Fri­day that it had opt­ed out of a part­ner­ship with Re­gen­eron to de­vel­op a fac­tor IX gene edit­ing ther­a­py. The part­ners had penned the deal in 2020, which made In­tel­lia re­spon­si­ble for 35% of de­vel­op­ment costs in ex­change for 35% of prof­its.

Re­gen­eron in Feb­ru­ary an­nounced that the FDA had cleared the gene in­ser­tion pro­gram to be test­ed in a clin­i­cal tri­al for peo­ple with he­mo­phil­ia B, which is slat­ed to be­gin in mid-2024. Re­gen­eron can still de­vel­op a CRISPR-based fac­tor IX ther­a­py un­der an ear­li­er li­cens­ing agree­ment, the biotech not­ed in its SEC fil­ing, mak­ing In­tel­lia el­i­gi­ble for up to $320 mil­lion in fu­ture mile­stones. In­tel­lia still has 35% stake in a fac­tor XI­II in­ser­tion pro­gram for he­mo­phil­ia A.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER